{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:16:05Z","timestamp":1794550565025,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41380-025-02931-3","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:24:37Z","timestamp":1739975077000},"page":"3443-3454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-194X","authenticated-orcid":false,"given":"Arianna","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Zelai","family":"Gar\u00e7on-Poca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9972-8187","authenticated-orcid":false,"given":"Amelie","family":"Essmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-5414","authenticated-orcid":false,"given":"Adriana Jesus","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-3739","authenticated-orcid":false,"given":"Francisco","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2931_CR1","unstructured":"Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief | Johnson & Johnson. 2023. https:\/\/www.jnj.com\/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief. Accessed 29 June 2023."},{"key":"2931_CR2","unstructured":"FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic | FDA. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed 29 June 2023."},{"key":"2931_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1176\/appi.ajp.2018.18040398","volume":"175","author":"AJ Rush","year":"2018","unstructured":"Rush AJ, Michael MD, Thase E. Improving depression outcome by patient-centered medical management. Am J Psychiatry. 2018;175:1187\u201398.","journal-title":"Am J Psychiatry"},{"key":"2931_CR4","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Sol\u00eds O, et al. Pharmacological and behavioral divergence of ketamine enantiomers:implications for abuse liability. Mol Psychiatry. 2021;26:6704\u201322. https:\/\/doi.org\/10.1038\/s41380-021-01093-2.","journal-title":"Mol Psychiatry"},{"key":"2931_CR5","doi-asserted-by":"publisher","first-page":"59334","DOI":"10.1371\/journal.pone.0059334","volume":"8","author":"BL Roth","year":"2013","unstructured":"Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, et al. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE. 2013;8:59334.","journal-title":"PLoS ONE"},{"key":"2931_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271:577\u201382.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2931_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jpsychires.2023.06.028","volume":"164","author":"ID Bandeira","year":"2023","unstructured":"Bandeira ID, Leal GC, Correia-Melo FS, Souza-Marques B, Silva SS, Lins-Silva DH, et al. Arketamine for bipolar depression: open-label, dose-escalation, Pilot Study. J Psychiatr Res. 2023;164:229\u201334.","journal-title":"J Psychiatr Res"},{"key":"2931_CR8","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","volume":"93","author":"MR Levinstein","year":"2022","unstructured":"Levinstein MR, Carlton ML, Di Ianni T, Ventriglia EN, Rizzo A, Gomez JL, et al. Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability. Biol Psychiatry. 2022;93:1118\u201326. https:\/\/doi.org\/10.1016\/j.biopsych.2022.12.019.","journal-title":"Biol Psychiatry"},{"key":"2931_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","volume":"210","author":"CL Nemeth","year":"2010","unstructured":"Nemeth CL, Paine TA, Rittiner JE, B\u00e9guin C, Carroll FI, Roth BL, et al. Role of kappa-opioid receptors in the effects of salvinorin a and ketamine on attention in rats. Psychopharmacology. 2010;210:263.","journal-title":"Psychopharmacology"},{"key":"2931_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","volume":"119","author":"A Gupta","year":"2011","unstructured":"Gupta A, Devi LA, Gomes I. Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011;119:294\u2013302.","journal-title":"J Neurochem"},{"key":"2931_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0022-3565(25)21501-4","volume":"230","author":"Y Itzhak","year":"1984","unstructured":"Itzhak Y, Simon EJ. A novel phencyclidine analog interacts selectively with mu opioid receptors. J Pharmacol Exp Ther. 1984;230:383\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"2931_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299\u20131313.e19.","journal-title":"Cell"},{"key":"2931_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"2931_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","volume":"23","author":"M Kokkinou","year":"2018","unstructured":"Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23:59\u201369.","journal-title":"Mol Psychiatry"},{"key":"2931_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","volume":"20","author":"P Belujon","year":"2017","unstructured":"Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017;20:1036\u201346.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2931_CR16","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1021\/jm00061a009","volume":"36","author":"Xshu He","year":"1993","unstructured":"He Xshu, Raymon LP, Mattson MV, Eldefrawi ME, de Costa BR. Synthesis and biological evaluation of 1-[1-(2-Benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and \u03c3-binding sites. J Med Chem. 1993;36:1188\u201393.","journal-title":"J Med Chem"},{"key":"2931_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/0091-3057(89)90020-8","volume":"32","author":"I Chaudieu","year":"1989","unstructured":"Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R. Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacol Biochem Behav. 1989;32:699\u2013705.","journal-title":"Pharmacol Biochem Behav"},{"key":"2931_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.mp.4001093","volume":"7","author":"S Kapur","year":"2002","unstructured":"Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - Implications for models of schizophrenia. Mol Psychiatry. 2002;7:837\u201344.","journal-title":"Mol Psychiatry"},{"key":"2931_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.mp.4001682","volume":"10","author":"P Seeman","year":"2005","unstructured":"Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry. 2005;10:877\u201383.","journal-title":"Mol Psychiatry"},{"key":"2931_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1124\/jpet.116.233627","volume":"358","author":"JM Witkin","year":"2016","unstructured":"Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, et al. The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits. J Pharmacol Exp Ther. 2016;358:71\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"2931_CR21","first-page":"20142516","volume":"282","author":"P Belujon","year":"2015","unstructured":"Belujon P, Grace AA. Regulation of dopamine system responsivity and its adaptive and pathological response to stress. Proc Biol Sci. 2015;282:20142516.","journal-title":"Proc Biol Sci"},{"key":"2931_CR22","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921.","journal-title":"J Neurosci"},{"key":"2931_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","volume":"7","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, \u00d8ye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25\u201338.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2931_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-3956(99)00031-X","volume":"34","author":"FX Vollenweider","year":"2000","unstructured":"Vollenweider FX, Vontobel P, \u00d8ye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000;34:35\u201343.","journal-title":"J Psychiatr Res"},{"key":"2931_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-02796-0","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, DiLeone RJ, Pittenger C, Duman RS. The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions. Transl Psychiatry. 2024;14:1\u201311.","journal-title":"Transl Psychiatry"},{"key":"2931_CR26","doi-asserted-by":"crossref","unstructured":"Ianni TD, Azadian MM, Ewbank SN, Michaelides M, Airan RD. Sex dependence of opioid-mediated responses to subanesthetic ketamine. Nat Commun. 2024;15:893.","DOI":"10.1038\/s41467-024-45157-7"},{"key":"2931_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0149-7634(05)80089-2","volume":"15","author":"JV Brady","year":"1991","unstructured":"Brady JV. Animal models for assessing drugs of abuse. Neurosci Biobehav Rev. 1991;15:35\u201343.","journal-title":"Neurosci Biobehav Rev"},{"key":"2931_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-0173(91)90007-U","volume":"16","author":"PW Kalivas","year":"1991","unstructured":"Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223\u201344.","journal-title":"Brain Res Brain Res Rev"},{"key":"2931_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/3-540-28082-0_2","volume":"169","author":"F Ohl","year":"2005","unstructured":"Ohl F. Animal models of anxiety. Handb Exp Pharmacol. 2005;169:35\u201369.","journal-title":"Handb Exp Pharmacol"},{"key":"2931_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nprot.2007.44","volume":"2","author":"AA Walf","year":"2007","unstructured":"Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2:322.","journal-title":"Nat Protoc"},{"key":"2931_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41592-020-0936-3","volume":"17","author":"T Patriarchi","year":"2020","unstructured":"Patriarchi T, Mohebi A, Sun J, Marley A, Liang R, Dong C, et al. An expanded palette of dopamine sensors for multiplex imaging in vivo. Nat Methods. 2020;17:1147\u201355.","journal-title":"Nat Methods"},{"key":"2931_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02493-4","volume":"13","author":"JD Keighron","year":"2023","unstructured":"Keighron JD, Bonaventura J, Li Y, Yang JW, DeMarco EM, Hersey M, et al. Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release. Transl Psychiatry. 2023;13:202.","journal-title":"Transl Psychiatry"},{"key":"2931_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0014-2999(81)90097-2","volume":"73","author":"Y Itzhak","year":"1981","unstructured":"Itzhak Y, Kalir A, Sarne Y. On the opioid nature of phencyclidine and its 3-hydroxy derivative. Eur J Pharmacol. 1981;73:229\u201333.","journal-title":"Eur J Pharmacol"},{"key":"2931_CR34","doi-asserted-by":"publisher","first-page":"88747","DOI":"10.3389\/fnbeh.2014.00188","volume":"8","author":"R Cachope","year":"2014","unstructured":"Cachope R, Cheer JF. Local control of striatal dopamine release. Front Behav Neurosci. 2014;8:88747.","journal-title":"Front Behav Neurosci"},{"key":"2931_CR35","doi-asserted-by":"publisher","first-page":"e1601631","DOI":"10.1126\/sciadv.1601631","volume":"3","author":"J Bonaventura","year":"2017","unstructured":"Bonaventura J, Quiroz C, Cai N-S, Rubinstein M, Tanda G, Ferr\u00e9 S. Key role of the dopamine D4 receptor in the modulation of corticostriatal glutamatergic neurotransmission. Sci Adv. 2017;3:e1601631.","journal-title":"Sci Adv"},{"key":"2931_CR36","doi-asserted-by":"crossref","unstructured":"Taniguchi J, Melani R, Chantranupong L, Wen MJ, Mohebi A, Berke JD, et al. Comment on \u2018Accumbens cholinergic interneurons dynamically promote dopamine release and enable motivation\u2019. eLife. 2024;13:e95694.","DOI":"10.7554\/eLife.95694"},{"key":"2931_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1126\/science.adh8287","volume":"382","author":"GD Stuber","year":"2023","unstructured":"Stuber GD. Neurocircuits for motivation. Science. 2023;382:394\u20138.","journal-title":"Science"},{"key":"2931_CR38","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00213-017-4660-3","volume":"234","author":"SA McDougall","year":"2017","unstructured":"McDougall SA, Moran AE, Baum TJ, Apodaca MG, Real V. Effects of ketamine on the unconditioned and conditioned locomotor activity of preadolescent and adolescent rats: impact of age, sex, and drug dose. Psychopharmacology. 2017;234:2683\u201396.","journal-title":"Psychopharmacology"},{"key":"2931_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.116.239228","volume":"361","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, et al. Antidepressant Potential of (R)-ketamine in rodent models: comparison with (S)-Ketamine. J Pharmacol Exp Ther. 2017;361:9\u201316.","journal-title":"J Pharmacol Exp Ther"},{"key":"2931_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress. 1998;11:125\u201336.","journal-title":"J Trauma Stress"},{"key":"2931_CR41","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891.","journal-title":"J Clin Psychiatry"},{"key":"2931_CR42","unstructured":"Pomrenze MB, Vaillancourt S, Llorach P, Rijsketic DR, Casey AB, Gregory N, et al. Opioid receptor expressing neurons of the central amygdala gate behavioral effects of ketamine in mice. bioRxiv:2024.03.03.583196 [Preprint]. 2024 Mar 6. Available from: https:\/\/www.biorxiv.org\/search\/2024.03.03.583196."},{"key":"2931_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","volume":"1562","author":"DDF Pacheco","year":"2014","unstructured":"Pacheco DDF, Romero TRL, Duarte IDG. Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors. Brain Res. 2014;1562:69\u201375.","journal-title":"Brain Res"},{"key":"2931_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24:1779\u201386.","journal-title":"Mol Psychiatry"},{"key":"2931_CR45","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci USA. 2020;117:2656\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2931_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019;76:337.","journal-title":"JAMA Psychiatry"},{"key":"2931_CR47","first-page":"211","volume":"48","author":"L Jelen","year":"2023","unstructured":"Jelen L, Lythgoe DJ, Daly OO, Stone JM, Young AH, Mehta MA. P345. attenuation of ketamine-induced glutamatergic activity and antidepressant effects by naltrexone pre-treatment, independent of changes in cerebral blood flow. Neuropsychopharmacology. 2023;48:211\u2013354.","journal-title":"Neuropsychopharmacology"},{"key":"2931_CR48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"2931_CR49","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","volume":"608","author":"LD Simmler","year":"2022","unstructured":"Simmler LD, Li Y, Hadjas LC, Hiver A, van Zessen R, L\u00fcscher C. Dual action of ketamine confines addiction liability. Nature. 2022;608:368\u201373.","journal-title":"Nature"},{"key":"2931_CR50","doi-asserted-by":"publisher","first-page":"eaat4422","DOI":"10.1126\/science.aat4422","volume":"360","author":"T Patriarchi","year":"2018","unstructured":"Patriarchi T, Cho JR, Merten K, Howe MW, Marley A, Xiong WH, et al. Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors. Science. 2018;360:eaat4422.","journal-title":"Science"},{"key":"2931_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218048","volume":"21","author":"MA Labouesse","year":"2020","unstructured":"Labouesse MA, Cola RB, Patriarchi T. GPCR-based dopamine sensors-a detailed guide to inform sensor choice for in vivo imaging. Int J Mol Sci. 2020;21:1\u201341.","journal-title":"Int J Mol Sci"},{"key":"2931_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01693-0","volume":"11","author":"JL Gomez","year":"2021","unstructured":"Gomez JL, Bonaventura J, Keighron J, Wright KM, Marable DL, Rodriguez LA, et al. Synaptic Zn2+ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior. Transl Psychiatry. 2021;11:570.","journal-title":"Transl Psychiatry"},{"key":"2931_CR53","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","volume":"27","author":"J Bonaventura","year":"2022","unstructured":"Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez-Soto M, Morris PJ, et al. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Mol Psychiatry. 2022;27:4144\u201356.","journal-title":"Mol Psychiatry"},{"key":"2931_CR54","doi-asserted-by":"publisher","first-page":"16446","DOI":"10.1073\/pnas.1105418108","volume":"108","author":"M Jalabert","year":"2011","unstructured":"Jalabert M, Bourdy R, Courtin J, Veinante P, Manzoni OJ, Barrot M, et al. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc Natl Acad Sci USA. 2011;108:16446\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2931_CR55","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1021\/acschemneuro.6b00397","volume":"8","author":"E Yavas","year":"2017","unstructured":"Yavas E, Young AMJ. N-Methyl-d-aspartate modulation of nucleus accumbens dopamine release by metabotropic glutamate receptors: fast cyclic voltammetry studies in rat brain slices in vitro. ACS Chem Neurosci. 2017;8:320\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"2931_CR56","first-page":"1449","volume":"14","author":"FSE Spencer","year":"2022","unstructured":"Spencer FSE, Glodkowska M, Sebold AI, Yavas E, Young AMJ. Attenuation of stimulated accumbal dopamine release by NMDA is mediated through metabotropic glutamate receptors. ACS Chem Neurosci. 2022;14:1449\u201358.","journal-title":"ACS Chem Neurosci"},{"key":"2931_CR57","doi-asserted-by":"publisher","first-page":"10585","DOI":"10.1523\/JNEUROSCI.23-33-10585.2003","volume":"23","author":"H Zhang","year":"2003","unstructured":"Zhang H, Sulzer D. Glutamate spillover in the striatum depresses dopaminergic transmission by activating group I metabotropic glutamate receptors. J Neurosci. 2003;23:10585\u201392.","journal-title":"J Neurosci"},{"key":"2931_CR58","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","volume":"190","author":"CG Abdallah","year":"2018","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther. 2018;190:148.","journal-title":"Pharmacol Ther"},{"key":"2931_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2019.10.008","volume":"60","author":"MW Mathis","year":"2020","unstructured":"Mathis MW, Mathis A. Deep learning tools for the measurement of animal behavior in neuroscience. Curr Opin Neurobiol. 2020;60:1\u201311.","journal-title":"Curr Opin Neurobiol"},{"key":"2931_CR60","doi-asserted-by":"publisher","first-page":"e66173","DOI":"10.7554\/eLife.66173","volume":"10","author":"BA Matikainen-Ankney","year":"2021","unstructured":"Matikainen-Ankney BA, Earnest T, Ali M, Casey E, Wang JG, Sutton AK, et al. Itle: An open-source device for measuring food intake and operant behavior in rodent home-cages. eLife. 2021;10:e66173.","journal-title":"eLife"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02931-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:22:05Z","timestamp":1757143325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02931-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2931"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-02931-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4624194\/v1","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}